2007
DOI: 10.1016/s1043-321x(07)80272-4
|View full text |Cite
|
Sign up to set email alerts
|

Pharmacogenomic Predictor of Sensitivity to Preoperative Chemotherapy With Paclitaxel and Fluorouracil, Doxorubicin, and Cyclophosphamide in Breast Cancer

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2018
2018
2021
2021

Publication Types

Select...
3

Relationship

0
3

Authors

Journals

citations
Cited by 3 publications
(1 citation statement)
references
References 0 publications
0
1
0
Order By: Relevance
“…Up to now, many signatures have been developed for pCR prediction (Hess et al, 2006;Thuerigen, 2006;Liedtke et al, 2009), but few studies have focused on the identification of extremely resistant patients. The pCR predictive signatures are based on risk scores summarized from quantitative transcriptional data, which have poor reproducibility (Borst and Wessels, 2010;Tabchy et al, 2010;Zhang et al, 2013;Qi et al, 2016) due to widespread batch effects and the uncertain quality of clinical samples.…”
Section: Introductionmentioning
confidence: 99%
“…Up to now, many signatures have been developed for pCR prediction (Hess et al, 2006;Thuerigen, 2006;Liedtke et al, 2009), but few studies have focused on the identification of extremely resistant patients. The pCR predictive signatures are based on risk scores summarized from quantitative transcriptional data, which have poor reproducibility (Borst and Wessels, 2010;Tabchy et al, 2010;Zhang et al, 2013;Qi et al, 2016) due to widespread batch effects and the uncertain quality of clinical samples.…”
Section: Introductionmentioning
confidence: 99%